Skip to menu Skip to content Skip to footer
Professor Mark Smithers
Professor

Mark Smithers

Email: 

Overview

Background

Emeritus Professor Mark Smithers is a surgical oncologist who specialises in surgery for oesophago-gastric diseases, melanoma, advanced skin cancer and soft tissue sarcoma. He was the Director of the Upper GI and Soft Tissue Unit at the Princess Alexandra Hospital, in Brisbane, Australia from 1998 - 2023. Commencing his academic career with the University of Queensland in 1987, he progressed to be the Mayne Chair in Surgery and head of the Academy of Surgery. He is the second University of Queensland Medical graduate to be appointed to this role. His research has been focussed on the development and assessment of outcomes from minimally invasive upper GI surgery, and trials assessing the role of perioperative multidisciplinary therapy for esophageal and gastric cancer. As well he has led, or been involved with, clinical trials from phase I to III, for all stages of melanoma through his role as the Chair of the Queensland Melanoma Project. More recently he has been involved with the assessment of access to, and outcomes from, surgery for cancer in Queensland, Australia.

He has overseen the administration and development of the surgery curriculum, and the teaching, in the Academy of Surgery, in the UQ Faculty of Medicine. He was on a number of committees relevant to the implementation of the UQ MD design course. He has held various leadership and committee roles with the Royal Australasian College of Surgeons, as well as leadership roles, including the Presidency, in the Australian and New Zealand Oesophago Gastric Surgeons Association. He has also been on the committees of international organisations related to oesophageal and gastric surgery. He has published 250 articles, eight book chapters, and has been on the editorial board of a number of surgical journals.

He has been recognised for his clinical and academic roles by the award of Member of the Order of Australia (AM). The citation reads, "for service to medicine in the fields of gastro-intestinal and melanoma surgery, to medical education and to professional organisations". The Royal Australasian College of Surgeons awarded him the Sir Hugh Devine medal, for services to surgery and the community. This is the College’s highest honour. Internationally, he has been awarded an honorary fellowship of the Royal College of Surgeons of Edinburgh and recently, in the United States, he was elected as an Honarary Fellow of the American Surgical Association.

Availability

Professor Mark Smithers is:
Not available for supervision
Media expert

Qualifications

  • Bachelor of Medicine and Surgery and Medical Science, The University of Queensland
  • Honorary Fellow, American Surgical Association, American Surgical Association
  • Fellow, Royal Australasian College of Surgeons, Royal Australasian College of Surgeons
  • Fellow, Royal College of Surgeons of Edinburgh, Royal College of Surgeons of Edinburgh
  • Fellow, Royal College of Surgeons of England, Royal College of Surgeons of England

Research interests

  • Cutaneous Melanoma

    epidemiology, public health issues and management of all stages

  • Management of Oesophageal and Gastric Cancer

    Investigation and management of benign and malignant diseases of the oesophagus and the stomach.

Works

Search Professor Mark Smithers’s works on UQ eSpace

414 works between 1983 and 2025

241 - 260 of 414 works

2012

Journal Article

An innovative approach for locally advanced stage III cutaneous melanoma: radiotherapy, followed by nodal dissection

Foote, Matthew, Burmeister, Bryan, Dwyer, Patrick, Burmeister, Elizabeth, Lambie, Duncan, Allan, Christopher, Barbour, Andrew, Bayley, Gerard, Pullar, Andrew, Meakin, Janelle, Thomas, Janine and Smithers, Mark (2012). An innovative approach for locally advanced stage III cutaneous melanoma: radiotherapy, followed by nodal dissection. Melanoma Research, 22 (3), 257-262. doi: 10.1097/CMR.0b013e3283531335

An innovative approach for locally advanced stage III cutaneous melanoma: radiotherapy, followed by nodal dissection

2012

Journal Article

Adjuvant radiotherapy versus observation alone for patients at risk of lymph-node field relapse after therapeutic lymphadenectomy for melanoma: a randomised trial

Burmeister, Bryan H., Henderson, Michael A., Ainslie, Jill, Fisher, Richard, Di Iulio, Juliana, Smithers, B. Mark, Hong, Angela, Shannon, Kerwin, Scolyer, Richard A., Carruthers, Scott, Coventry, Brendon J., Babington, Scott, Duprat, Joao, Hoekstra, Harald J. and Thompson, John F. (2012). Adjuvant radiotherapy versus observation alone for patients at risk of lymph-node field relapse after therapeutic lymphadenectomy for melanoma: a randomised trial. Lancet Oncology, 13 (6), 589-597. doi: 10.1016/S1470-2045(12)70138-9

Adjuvant radiotherapy versus observation alone for patients at risk of lymph-node field relapse after therapeutic lymphadenectomy for melanoma: a randomised trial

2012

Conference Publication

TOPGEAR: An international randomized phase III trial of preoperative chemoradiotherapy versus preoperative chemotherapy for resectable gastric cancer (AGITG/TROG/EORTC/NCIC CTG)

Leong, Trevor, Smithers, Mark, Michael, Michael, Gebski, Val, Boussioutas, Alex, Miller, Danielle, Zalcberg, John Raymond, Wong, Rebecca and Haustermans, Karin (2012). TOPGEAR: An international randomized phase III trial of preoperative chemoradiotherapy versus preoperative chemotherapy for resectable gastric cancer (AGITG/TROG/EORTC/NCIC CTG). 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago Il, Jun 01-06, 2012. ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY.

TOPGEAR: An international randomized phase III trial of preoperative chemoradiotherapy versus preoperative chemotherapy for resectable gastric cancer (AGITG/TROG/EORTC/NCIC CTG)

2012

Conference Publication

Long-term cure after complete resection and adjuvant immunotherapy for distant melanoma metastases

Morton, Donald L., Mozzillo, Nicola, Kashani-Sabet, Mohammed, Thompson, John F., Kelley, Mark C., De Conti, Ronald C., Lee, Jeffrey Edwin, Huth, James F., Faries, Mark B., Dalgleish, Angus George, Wagner, Jeffrey D., Hersh, Evan, Schneebaum, Schlomo, Anderson, Clay M., Smithers, Mark, Schuchter, Lynn Mara, McMasters, Kelly M., Testori, Alessandro, Karakousis, C. P. and Elashoff, Robert (2012). Long-term cure after complete resection and adjuvant immunotherapy for distant melanoma metastases. 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago Il, Jun 01-06, 2012. ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY.

Long-term cure after complete resection and adjuvant immunotherapy for distant melanoma metastases

2012

Journal Article

Population-based 20-year survival among people diagnosed with thin melanomas in Queensland, Australia

Green, Adele C., Baade, Peter, Coory, Michael, Aitken, Joanne F. and Smithers, Mark (2012). Population-based 20-year survival among people diagnosed with thin melanomas in Queensland, Australia. Journal of Clinical Oncology, 30 (13), 1462-1467. doi: 10.1200/JCO.2011.38.8561

Population-based 20-year survival among people diagnosed with thin melanomas in Queensland, Australia

2012

Conference Publication

TOPGEAR: An international randomized phase III trial of preoperative chemoradiotherapy versus preoperative chemotherapy for resectable gastric cancer (AGITG/TROG/EORTC/NCIC CTG)

Leong, Trevor, Smithers, Mark, Michael, Michael, Gebski, Val, Boussioutas, Alex, Miller, Danielle, Zalcberg, John Raymond, Wong, Rebecca and Haustermans, Karin (2012). TOPGEAR: An international randomized phase III trial of preoperative chemoradiotherapy versus preoperative chemotherapy for resectable gastric cancer (AGITG/TROG/EORTC/NCIC CTG). 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago Il, Jun 01-06, 2012. ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY.

TOPGEAR: An international randomized phase III trial of preoperative chemoradiotherapy versus preoperative chemotherapy for resectable gastric cancer (AGITG/TROG/EORTC/NCIC CTG)

2012

Journal Article

Predictors of survival among patients diagnosed with adenocarcinoma of the esophagus and gastroesophageal junction

Thrift, Aaron P., Nagle, Christina M., Fahey, Paul P., Smithers, Bernard M., Watson, David I. and Whiteman, David C. (2012). Predictors of survival among patients diagnosed with adenocarcinoma of the esophagus and gastroesophageal junction. Cancer Causes and Control, 23 (4), 555-564. doi: 10.1007/s10552-012-9913-1

Predictors of survival among patients diagnosed with adenocarcinoma of the esophagus and gastroesophageal junction

2012

Conference Publication

Melanoma brain metastases: the impact of nodal disease

Jackson, J., Burmeister, B. H., Burmeister, E., Foote, M. C., Thomas, J. M. and Smithers, B. M. (2012). Melanoma brain metastases: the impact of nodal disease. 54th Annual Meeting of the American Society for Radiation Oncology (ASTRO), Boston, MA United States, 28-31 October 2012. Philadelphia, PA United States: Elsevier. doi: 10.1016/j.ijrobp.2012.07.1748

Melanoma brain metastases: the impact of nodal disease

2012

Conference Publication

DOCTOR: A randomized phase II trial of preoperative cisplatin, 5-fluorouracil, and docetaxel with or without radiotherapy based on poor early response to standard chemotherapy for resectable adenocarcinoma of the esophagus and/or OG junction

Barbour, Andrew, Smithers, Bernard Mark, Burmeister, Bryan, Zalcberg, John Raymond, Spry, Nigel, Smith, Garrett, Wilson, Kate, Roff, Kate, Yip, Sonia and Walpole, Euan Thomas (2012). DOCTOR: A randomized phase II trial of preoperative cisplatin, 5-fluorouracil, and docetaxel with or without radiotherapy based on poor early response to standard chemotherapy for resectable adenocarcinoma of the esophagus and/or OG junction. 48th Annual Meeting of the American Society of Clinical Oncology (ASCO), Chicago, Il United States, 01-06 June 2012. Alexandria, VA United States: American Society of Clinical Oncology.

DOCTOR: A randomized phase II trial of preoperative cisplatin, 5-fluorouracil, and docetaxel with or without radiotherapy based on poor early response to standard chemotherapy for resectable adenocarcinoma of the esophagus and/or OG junction

2012

Conference Publication

Immuno-chemoablation of metastatic melanoma with intralesional Rose Bengal

Agarwala, S. S., Thompson, J. F., Smithers, B. M., Ross, M., Coventry, B. J., Minor, D. R., Scoggins, C. R. and Wachter, E. (2012). Immuno-chemoablation of metastatic melanoma with intralesional Rose Bengal. 37th Congress of the European Society for Medical Oncology (ESMO), Vienna Austria, 28 September-02 October 2012. Oxford, United Kingdom: Oxford University Press. doi: 10.1093/annonc/mds404

Immuno-chemoablation of metastatic melanoma with intralesional Rose Bengal

2012

Journal Article

The influence of pre-diagnostic demographic and lifestyle factors on oesophageal squamous cell carcinoma survival

Thrift, Aaron P., Nagle, Christina M., Fahey, Paul P., Russell, Anne, Smithers, Bernard M., Watson, David I., Whiteman, David C. and for the Australian Cancer Study Clinical Follow-Up Study (2012). The influence of pre-diagnostic demographic and lifestyle factors on oesophageal squamous cell carcinoma survival. International Journal of Cancer, Early online (5), 1-29. doi: 10.1002/ijc.27420

The influence of pre-diagnostic demographic and lifestyle factors on oesophageal squamous cell carcinoma survival

2012

Conference Publication

Activation of stat5 is an indicator of good prognosis in stage Ib and II melanomas

Rodero, M., Wright, A., Malt, M., Smithers, M., Green, A. and Khosrotehrani, K. (2012). Activation of stat5 is an indicator of good prognosis in stage Ib and II melanomas. The Australasian College of Dermatologists 45th Annual Scientific Meeting, Brisbane, QLD, Australia, 20-23 May 2012. Richmond, VIC, Australia: Wiley-Blackwell Publishing Asia. doi: 10.1111/j.1440-0960.2012.00892.x

Activation of stat5 is an indicator of good prognosis in stage Ib and II melanomas

2012

Conference Publication

MAGE-A3 expression in patients screened for the DERMA trial: a phase III trial testing MAGE-A3 immunotherapeutic in the adjuvant setting for stage IIIB-C-Tx melanoma

Thompson, John F., Santinami, Mario, Jouary, Thomas, Levchenko, Eugeny, Smithers, Bernard Mark, Mortier, Laurent, Grob, Jean Jacques, Trefzer, Uwe, Gutzmer, Ralf, Jamoul, Corinne, Peeters, Olivier, Dreno, Brigitte and Kirkwood, John M. (2012). MAGE-A3 expression in patients screened for the DERMA trial: a phase III trial testing MAGE-A3 immunotherapeutic in the adjuvant setting for stage IIIB-C-Tx melanoma. 48th Annual Meeting of the American Society of Clinical Oncology (ASCO), Chicago, Illinois, 1-6 June 2012 . Alexandria, VA, United States : American Society of Clinical Oncology.

MAGE-A3 expression in patients screened for the DERMA trial: a phase III trial testing MAGE-A3 immunotherapeutic in the adjuvant setting for stage IIIB-C-Tx melanoma

2012

Conference Publication

Gene expression analysis of EAC in association with PET response.

Wayte, Nicola, Nancarrow, Derek, Walpole, Euan Thomas, Lampe, Guy, Gotley, David, Smithers, Bernard Mark and Barbour, Andrew (2012). Gene expression analysis of EAC in association with PET response.. ASCO GI Symposium, San Diego, CA United States, 24 January 2012. Alexandria, VA United States: American Society of Clinical Oncology. doi: 10.1200/jco.2012.30.4_suppl.50

Gene expression analysis of EAC in association with PET response.

2011

Journal Article

Local therapies and resection in Barrett's oesophagus and early oesophagogastric cancer

Tan, Alyisha, Macrae, Finlay and Smithers B. Mark (2011). Local therapies and resection in Barrett's oesophagus and early oesophagogastric cancer. Cancer Forum, 35 (3), 141-145.

Local therapies and resection in Barrett's oesophagus and early oesophagogastric cancer

2011

Journal Article

Whole genome expression array profiling highlights differences in mucosal defense genes in barrett's esophagus and esophageal adenocarcinoma

Nancarrow, Derek J., Clouston, Andrew D., Smithers, B. Mark, Gotley, David C., Drew, Paul A., Watson, David I., Tyagi, Sonika, Hayward, Nicholas K. and Whiteman, David C. (2011). Whole genome expression array profiling highlights differences in mucosal defense genes in barrett's esophagus and esophageal adenocarcinoma. Plos One, 6 (7) e22513, e22513-1-e22513-15. doi: 10.1371/journal.pone.0022513

Whole genome expression array profiling highlights differences in mucosal defense genes in barrett's esophagus and esophageal adenocarcinoma

2011

Journal Article

Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis

Sjoquist, Katrin M., Burmeister, Bryan H., Smithers, B. Mark, Zalcberg, John R., Simes, R. John, Barbour, Andrew, Gebski, Val and for the Australasian Gastro-Intestinal Trials Group (2011). Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncology, 12 (7), 681-692. doi: 10.1016/S1470-2045(11)70142-5

Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis

2011

Journal Article

Defining cure for esophageal cancer: Analysis of actual 5-year survivors following esophagectomy

Hirst, Jodi, Smithers, Bernard Mark, Gotley, David C., Thomas, Janine and Barbour, Andrew (2011). Defining cure for esophageal cancer: Analysis of actual 5-year survivors following esophagectomy. Annals of Surgical Oncology, 18 (6), 1766-1774. doi: 10.1245/s10434-010-1508-z

Defining cure for esophageal cancer: Analysis of actual 5-year survivors following esophagectomy

2011

Conference Publication

Dermoscopic naevus patterns by age and body site in the high risk and general Queensland populations

Douglas, N. C., Borgovan, T., Carroll, M. J., Siskind, V., Wurm, E. M. T., Smithers, B. M., Green, A. C. and Soyer, H. P. (2011). Dermoscopic naevus patterns by age and body site in the high risk and general Queensland populations. MALDEN: WILEY-BLACKWELL.

Dermoscopic naevus patterns by age and body site in the high risk and general Queensland populations

2011

Journal Article

Trends in melanoma incidence among children: Possible influence of sun-protection programs

Baade, Peter D., Green, Adele C., Smithers, Bernard Mark and Aitken, Joanne F. (2011). Trends in melanoma incidence among children: Possible influence of sun-protection programs. Expert Review of Anticancer Therapy, 11 (5), 661-664. doi: 10.1586/ERA.11.28

Trends in melanoma incidence among children: Possible influence of sun-protection programs

Funding

Current funding

  • 2024 - 2025
    Optimising the Diagnosis and Management of Unilateral Primary Aldosteronism (MSH SERTA Grant led by Metro South HHS)
    Metro South Hospital and Health Service
    Open grant
  • 2023 - 2026
    iCare - An interactive online portal to improve health and wellbeing for people living with complex cancers, and their informal carers: a Phase II randomised controlled trial (Ex led Deakin MRFF CTA)
    Deakin University
    Open grant
  • 2021 - 2026
    AGITG TOP GEAR: A randomised phase II/III trial of preoperative chemoradiotherapy versus preoperative chemotherapy for resectable gastric cancer (CTCS: led by USyd)
    University of Sydney
    Open grant
  • 2019 - 2026
    A Randomised Phase II Trial of Adjuvant Avelumab in Patients with Early Stage Merkel Cell Carcinoma
    NHMRC MRFF - Rare Cancers, Rare Diseases and Unmet Need
    Open grant
  • 2019 - 2025
    Melanoma Margins Trial II - A Phase III, Multi-centre Randomised Controlled Trial Investigating 1cm v 2cm Wide Surgical Excision Margins.. (NHMRC Project Grant led by the University of Melbourne).
    University of Melbourne
    Open grant

Past funding

  • 2021 - 2024
    Advanced technological approach to predicting survival in patients diagnosed with locally invasive cutaneous melanoma
    Cancer Council Queensland
    Open grant
  • 2021 - 2024
    Establishing Australia's First Familial Melanoma Clinic (MSH RSS SERTA Program Grant led by Metro South Hospital and Health Service)
    Metro South Hospital and Health Service
    Open grant
  • 2020 - 2021
    Cancer Evolution Biobank
    PA Research Foundation
    Open grant
  • 2017 - 2019
    Predictors of mortality in thin melanomas
    Cancer Council Queensland
    Open grant
  • 2013 - 2015
    To identify and assess markers of prognosis, response and resistance to therapy in patients with Stage III metastatic melanoma
    Cancer Bequest Fund
    Open grant
  • 2011
    DOCetaxel with or without radiation Therapy for resectable Oesophageal adenocarcinoma based on early PET Response to induction chemotherapy (DOCTOR)
    NHMRC Project Grant
    Open grant
  • 2011 - 2013
    Effects of nevogenesis susceptibility genes and phenotypic correlation with dermoscopic characteristics of nevi
    NHMRC Project Grant
    Open grant
  • 2010 - 2014
    Comparison of pre- and perioperative immunonutrition in patients undergoing surgical resection of oesophageal cancer (NHMRC Project Grant administered by the University of Adelaide)
    University of Adelaide
    Open grant
  • 2001 - 2002
    The epidemiology of oesophageal cancer: Risk and molecular markers
    Queensland Cancer Fund
    Open grant
  • 2000
    The role of TAP and MHC class I expression in the response to melanoma immunotherapy using autologous dendritic cells
    Princess Alexandra Hospital R&D Foundation
    Open grant
  • 1999 - 2000
    A phase II clinical trial in patients with metastatic melanoma comparing autologous dendritic cells pulsed with autologous tumour peptides and melanoma associated peptides linked to the endoplasmic re
    Queensland Cancer Fund
    Open grant
  • 1998
    A Phase I/II Clinical Trial to Test Tumour Vaccines Comprising with Protein or Autologous Tumour Antigen Autologous Dandritic Cells Generated in a Closed Bag System Pulsed
    Mayne Bequest Fund
    Open grant
  • 1998
    Isolated limb infusion of melphalan and microdialysis technique in treatment of recurrent malignant melanoma
    Princess Alexandra Hospital R&D Foundation
    Open grant
  • 1998 - 2000
    Treatment of Recurrent Malignant Melanoma by Limb Infusion of Cytotoxic Drugs and Other Techniques
    NHMRC Project Grant
    Open grant
  • 1997 - 1998
    Pharmacokinetics of tumour necrosis factor (TNF) in isolated rat hindlimb perfusions and infusions related to melanoma therapy
    Princess Alexandra Hospital R&D Foundation
    Open grant
  • 1996 - 1997
    Targeting and monitoring drug delivery in specific tissues using iontophoresis and microdialysis
    Quality Funds Round 3
    Open grant
  • 1995 - 1997
    Pharmacokinetics of melphalan in isolated limb perfusion and infusion
    Queensland Cancer Fund
    Open grant

Supervision

Availability

Professor Mark Smithers is:
Not available for supervision

Supervision history

Current supervision

  • Master Philosophy

    Assessment of the impact of treating service characteristics on surgical and oncological outcomes for patients with Retroperitoneal and Inguinal Sarcomas in Queensland

    Principal Advisor

    Other advisors: Professor Andrew Barbour

  • Master Philosophy

    Factors Influencing Anastomotic Complications after Oesophagectomy

    Associate Advisor

  • Doctor Philosophy

    New tools for the multi-modal evaluation of pancreatic cancer and its precursor neoplasms.

    Associate Advisor

    Other advisors: Dr David Cavallucci

Completed supervision

Media

Enquiries

Contact Professor Mark Smithers directly for media enquiries about:

  • Advanced endoscopic surgery
  • Cancer surgery
  • Endoscopic surgery
  • General surgery
  • Melanoma
  • Surgery - cancer
  • Surgery - oesophageal, gastric cancer
  • Surgery - upper GI
  • Upper GI surgery

Need help?

For help with finding experts, story ideas and media enquiries, contact our Media team:

communications@uq.edu.au